Public domain "acetylsalicylic acid" (2-acetoxybenzoic acid) is better known as "aspirin" in the United States—a generic term. In Canada, however, "Aspirin", with an uppercase A, is still a trademark of the German company Bayer, while aspirin, with a lowercase "a", is not. Bayer lost the trademark in the United States, the UK and France after World War I, as part of the Treaty of Versailles. So many copycat products entered the marketplace during the war that it was deemed generic just three years later. Bayer also lost the trademark in the same jurisdictions for "Heroin" which it trademarked a year before it
Obeticholic acid synthesis, have been found in this condition. FGF19 is potently stimulated by bile acids and especially by OCA. A proof of concept study of OCA (25 mg/d) has shown clinical and biochemical benefit. On February 1, 2018, the FDA updated label warnings for Obeticholic acid to better explain recommended dosing. According to the agency, misunderstanding led some health care professionals to improperly dose the drug on a daily basis rather than weekly, which can increase the risk of liver damage. Obeticholic acid Obeticholic acid (abbreviated to OCA, trade name Ocaliva), is a semi-synthetic bile acid analogue which has the chemical